Ask AI

Bridging Discoveries to Practice: CCO's Conference to Clinic Highlights From the 2025 ASH Annual Meeting *

Review certified expert analysis text modules, podcasts, and Capsule Summaries highlighting key studies from the 2025 ASH annual meeting.

Share

Program Content

6 Capsule Summaries

Activities

CLL17
CLL17: Phase III Trial of Continuous Ibrutinib vs Fixed-Duration Venetoclax Plus Obinutuzumab or Venetoclax Plus Ibrutinib for Untreated CLL
Conference Coverage
Slideset
Congratulations: You achieved a completion on 04/09/2022

Released: December 10, 2025

CaDAnCe 101
CaDAnCe-101 Update: Phase I Study Evaluating BTK Degrader BGB-16673 in R/R CLL/SLL
Conference Coverage
Slideset
Congratulations: You achieved a completion on 04/09/2022

Released: December 11, 2025

Sonrotoclax RR MCL
Phase I/II Trial of Sonrotoclax (BGB-11417) in R/R Mantle Cell Lymphoma After Prior BTK Inhibitor Therapy 
Conference Coverage
Slideset
Congratulations: You achieved a completion on 04/09/2022

Released: December 11, 2025

BRUIN CLL 314
BRUIN CLL-314: Pirtobrutinib vs Ibrutinib in Treatment-Naive and BTKi-Naive R/R CLL/SLL
Conference Coverage
Slideset
Congratulations: You achieved a completion on 04/09/2022

Released: December 12, 2025

Surovatamig RR FL
Phase I Trial of CD19 x CD3 T-Cell Engager Surovatamig (AZD0486) in R/R Follicular Lymphoma: 3-Yr Follow-up
Conference Coverage
Slideset
Congratulations: You achieved a completion on 04/09/2022

Released: December 12, 2025

BRUIN CLL 313
BRUIN CLL-313: Pirtobrutinib vs Bendamustine + Rituximab in Treatment-Naive CLL/SLL
Conference Coverage
Slideset
Congratulations: You achieved a completion on 04/09/2022

Released: December 12, 2025

Activities

PulseCast Lymphomas ASH 2025
PulseCast: Highlights in Lymphomas From the 2025 ASH Annual Meeting
Conference Coverage
Podcast Episodes
Congratulations: You achieved a completion on 04/09/2022

Released: December 19, 2025

2025 ASH Lymphomas
Key Studies in Lymphomas/CLL: Independent Conference Coverage of the 2025 ASH Annual Meeting
Conference Coverage
Text Module
Congratulations: You achieved a completion on 04/09/2022

Released: February 26, 2026

Expires: August 25, 2026

6 Capsule Summaries

Activities

SAVE Trial
SAVE: Phase I/II Study of Oral Revumenib Plus Decitabine/Cedazuridine and Venetoclax in Cohort of Patients with Newly Diagnosed AML
Conference Coverage
Slideset
Congratulations: You achieved a completion on 04/09/2022

Released: December 08, 2025

ASC2ESCALATE
ASC2ESCALATE: Asciminib in Patients With Chronic-Phase CML After 1 Prior TKI
Conference Coverage
Slideset
Congratulations: You achieved a completion on 04/09/2022

Released: December 11, 2025

VICEROY
VICEROY: Venetoclax + Azacitidine + Gilteritinib in Patients With ND FLT3-Mutated AML Ineligible for Intensive Induction Chemotherapy
Conference Coverage
Slideset
Congratulations: You achieved a completion on 04/09/2022

Released: December 12, 2025

PARADIGM
PARADIGM: Randomized Phase II Trial of Azacitidine + Venetoclax vs Conventional Intensive Chemotherapy for Fit Patients With Newly Diagnosed AML
Conference Coverage
Slideset
Congratulations: You achieved a completion on 04/09/2022

Released: December 12, 2025

FASCINATION
Phase II FASCINATION: 3-Yr Update of Asciminib + Conventional BCR::ABL1 Inhibitors in Newly Diagnosed CML
Conference Coverage
Slideset
Congratulations: You achieved a completion on 04/09/2022

Released: December 12, 2025

KOMET 007
KOMET-007: Phase Ib Study of Ziftomenib + Venetoclax/Azacitidine in Newly Diagnosed NPM1-Mutated Acute Myeloid Leukemia
Conference Coverage
Slideset
Congratulations: You achieved a completion on 04/09/2022

Released: December 16, 2025

Activities

ASH 2025: Key Studies in Leukemias
Conference to Clinic Highlights From the 2025 ASH Annual Meeting: Key Studies in Leukemias
Conference Coverage
Text Module
Congratulations: You achieved a completion on 04/09/2022

Released: February 27, 2026

Expires: August 26, 2026

PulseCast Leukemias ASH 2025
PulseCast: Highlights in Leukemias From the 2025 ASH Annual Meeting
Conference Coverage
Podcast Episodes
Congratulations: You achieved a completion on 04/09/2022

Released: December 18, 2025

7 Capsule Summaries

Activities

DURGA 1
DURGA-1: Phase Ib/II Study of AZD0120, a BCMA/CD19 Dual-Targeting CAR T-Cell Therapy, in R/R MM
Conference Coverage
Slideset
Congratulations: You achieved a completion on 04/09/2022

Released: December 09, 2025

CAMMA 1 Updated Analysis
CAMMA 1: Updated Safety, Efficacy, and Biomarker Analyses From Phase I Study of Cevostamab + Pomalidomide + Dexamethasone in BCMA1-Naive RRMM
Conference Coverage
Slideset
Congratulations: You achieved a completion on 04/09/2022

Released: December 09, 2025

Cilta cel for Standard Risk RRMM
Extended Efficacy and Safety Outcomes With Ciltacabtagene Autoleucel (Cilta-cel) in Patients With R/R MM With Standard-Risk Cytogenetics
Conference Coverage
Slideset
Congratulations: You achieved a completion on 04/09/2022

Released: December 09, 2025

Cevostamab Consolidation in RR MM
Phase II Trial of Cevostamab Consolidation After Anti-BCMA CAR T-Cell Therapy in R/R MM
Conference Coverage
Slideset
Congratulations: You achieved a completion on 04/09/2022

Released: December 10, 2025

iMMagine 1
iMMagine-1 Update: Phase II Study of D-Domain BCMA-Directed CAR T-Cell Therapy, Anitocabtagene Autoleucel, in R/R MM
Conference Coverage
Slideset
Congratulations: You achieved a completion on 04/09/2022

Released: December 10, 2025

RedirecTT 1 Update
RedirecTT-1 Update: Talquetamab + Teclistamab in Relapsed/Refractory MM With Extramedullary Disease
Conference Coverage
Slideset
Congratulations: You achieved a completion on 04/09/2022

Released: December 12, 2025

MajesTEC3
MajesTEC-3: Teclistamab + Daratumumab vs Daratumumab-Based Regimens (DPd/DVd) in Patients With R/R Multiple Myeloma
Conference Coverage
Slideset
Congratulations: You achieved a completion on 04/09/2022

Released: December 12, 2025

Activities

PulseCast Multiple Myeloma ASH 2025
PulseCast: Highlights in Multiple Myeloma From the 2025 ASH Annual Meeting
Conference Coverage
Podcast Episodes
Congratulations: You achieved a completion on 04/09/2022

Released: December 23, 2025

6 Capsule Summaries

Activities

INCA033989 in ET
Phase I Trial of INCA033989, a First-in-Class Antibody Targeting Mutant Calreticulin: Safety and Efficacy in Essential Thrombocythemia
Conference Coverage
Slideset
Congratulations: You achieved a completion on 04/09/2022

Released: December 09, 2025

IMerge Post Hoc Analysis
IMerge Post Hoc Analysis: Treatment-Emergent Cytopenias and Response With Imetelstat in Patients With Lower-Risk MDS
Conference Coverage
Slideset
Congratulations: You achieved a completion on 04/09/2022

Released: December 10, 2025

VERONA Subgroup Analyses
VERONA: Subgroup Analyses of Venetoclax or Placebo Combined With Azacitidine in Treatment-Naive Higher-Risk MDS
Conference Coverage
Slideset
Congratulations: You achieved a completion on 04/09/2022

Released: December 10, 2025

INCA033989 in MF
Preliminary Results From 2 Phase I Trials Exploring the Mutant Calreticulin-Specific mAb INCA033989 ± Ruxolitinib in Patients With MF
Conference Coverage
Slideset
Congratulations: You achieved a completion on 04/09/2022

Released: December 11, 2025

MANIFEST 2 96 Wk Update
MANIFEST-2 96-Wk Update: Ruxolitinib + Pelabresib or Placebo in Patients With JAK Inhibitor–Naive MF
Case Challenge
Slideset
Congratulations: You achieved a completion on 04/09/2022

Released: December 12, 2025

Reduced Duration HMA in LR MDS
Randomized Phase II Trial of Reduced Treatment Durations With Hypomethylating Agents in Lower-Risk MDS
Conference Coverage
Slideset
Congratulations: You achieved a completion on 04/09/2022

Released: December 17, 2025

Activities

PulseCast MDS MPNs ASH 2025
PulseCast: Highlights in MDS/MPNs From the 2025 ASH Annual Meeting
Conference Coverage
Podcast Episodes
Congratulations: You achieved a completion on 04/09/2022

Released: December 30, 2025

ASH 2025 MDS and MPNs
New Data and Clinical Implications in MPNs and MDS: ASH 2025 Highlights
Conference Coverage
Text Module
Congratulations: You achieved a completion on 04/09/2022

Released: February 26, 2026

Expires: August 25, 2026

5 Capsule Summaries

Activities

VAYHIT3
VAYHIT3: Secondary Analysis of Phase II Trial of Ianalumab in Patients With Previously Treated Primary ITP
Conference Coverage
Slideset
Congratulations: You achieved a completion on 04/09/2022

Released: December 12, 2025

VAYHIT2
VAYHIT2: Phase III Trial of Eltrombopag ± Ianalumab, an Anti-BAFF Receptor Monoclonal Antibody, as Second-line Therapy for Primary ITP
Conference Coverage
Slideset
Congratulations: You achieved a completion on 04/09/2022

Released: December 12, 2025

VIVID 3
VIVID 3: Phase I/II Study of VGA039, a Novel Protein S Antibody, as Maintenance Therapy in Patients With von Willebrand Disease
Conference Coverage
Slideset
Congratulations: You achieved a completion on 04/09/2022

Released: December 15, 2025

RWE of IV Iron in IDA
Real-world Evidence Study of IV Iron Use During Acute Infection in Patients With Iron Deficiency Anemia
Conference Coverage
Slideset
Congratulations: You achieved a completion on 04/09/2022

Released: December 16, 2025

ICI ITP
Multicenter Cohort Study of ICI-Associated Immune Thrombocytopenia Incidence and Outcomes in Adults Receiving Care at US Academic Centers
Conference Coverage
Slideset
Congratulations: You achieved a completion on 04/09/2022

Released: December 16, 2025

Activities

PulseCast Nonmalignant Disorders ASH 2025
PulseCast: Highlights in Nonmalignant Blood Disorders From the 2025 ASH Annual Meeting
Conference Coverage
Podcast Episodes
Congratulations: You achieved a completion on 04/09/2022

Released: December 18, 2025

ASH 2025 Nonmalignant Hematologic Disorders
Emerging Data and Clinical Implications in Nonmalignant Hematologic Disorders: ASH 2025 Highlights
Conference Coverage
Text Module
Congratulations: You achieved a completion on 04/09/2022

Released: February 20, 2026

Expires: August 19, 2026

Faculty

cover img faculity

Jeremy S. Abramson, MD, MMSc

Professor of Medicine
Harvard Medical School
Director, Center for Lymphoma
Mass General Brigham Cancer Institute
Boston, Massachusetts

cover img faculity

Hanny Al-Samkari, MD

The Peggy S. Blitz Endowed Chair in Hematology/Oncology
Massachusetts General Hospital
Associate Professor of Medicine
Harvard Medical School
Boston, Massachusetts

cover img faculity

Courtney D. DiNardo, MD, MSCE

Professor of Medicine
Department of Leukemia
UT MD Anderson Cancer Center
Houston, Texas

cover img faculity

Amir T. Fathi, MD

Director, Leukemia Program
Massachusetts General Hospital
Associate Professor of Medicine
Harvard Medical School
Boston, Massachusetts

cover img faculity

Brad Kahl, MD

Professor of Medicine
Washington University School of Medicine
Director Lymphoma Program
Siteman Cancer Center
St Louis, Missouri

cover img faculity

Rami Komrokji, MD

Senior Member, Vice Chair
Section Head – Leukemia and MDS
Department of Malignant Hematology
H. Lee Moffitt Cancer Center
Professor of Oncologic Sciences
University of South Florida
Tampa, Florida

cover img faculity

Shaji K. Kumar, MD

Mark and Judy Mullins Professor of Hematological Malignancies
Consultant, Division of Hematology
Professor of Medicine
Research Chair, Division of Hematology
Mayo Clinic
Rochester, Minnesota

cover img faculity

Joseph J. Shatzel, MD, MCR

Associate Professor of Medicine
Oregon Health & Science University
Knight Cancer Institute
Portland, Oregon

cover img faculity

Amer Zeidan, MBBS, MHS

Professor of Internal Medicine (Hematology)
Chief, Division of Hematologic Malignancies
Assistant Medical Director, Hematology, Clinical Trials Office (CTO)
Director, Hematology Early Therapeutics Research
Director, Leukemia and Myeloid Malignancies Program
Leader, Leukemia and Myeloid Malignancies Clinical Research Team (CRT)
Section of Hematology, Department of Internal Medicine, Yale School of Medicine
Yale Comprehensive Cancer Center and Smilow Cancer Hospital
New Haven, Connecticut

Provided by

ProCE Banner

Provided by Clinical Care Options, LLC dba Decera Clinical Education in partnership with Smart Patients.

Supporters

Supported by educational grants from AstraZeneca, BeOne Medicines, Genentech, Geron Corporation, Incyte, Johnson & Johnson, Lilly, and Novartis Pharmaceuticals Corporation.

AstraZeneca

BeOne Medicines

Genentech

Geron Corporation

Incyte

Johnson & Johnson

Lilly

Novartis Pharmaceuticals Corporation

Partners

Smart Patients

ProCE Banner

*Decera Clinical Education is an independent medical education company that provides state-of-the-art medical information to healthcare professionals through conference coverage and other educational programs.